Literature DB >> 23777020

Profile of mixed species (Plasmodium vivax and falciparum) malaria in adults.

M K Mohapatra1, L K Dash, P K Barih, P C Karua.   

Abstract

OBJECTIVE: Studies on malaria due to co-existent P. falciparum and P. vivax infections are negligible in India. Therefore, this study was undertaken to find out the clinical profile, prognostic factors, and outcome of mixed species malaria and to compare it with P. falciparum malaria.
METHODS: This prospective, comparative study has been conducted in a tertiary health care institution with high prevalence of malaria. A cohort of 888 patients of malaria was enrolled in this study. The diagnosis of malaria was made either by Giemsa stained peripheral blood smear or RDT. Mixed species (MS) malaria was diagnosed when both P. vivax and P. falciparum were detected either from peripheral blood smear or RDT. Patients with P. falciparum malaria were grouped in to Pf group. The differences in clinical presentation, biochemical and haematological findings, occurrence of severe malaria, and outcome were recorded, compared, and analyzed. The severity of complication was assessed and Malaria Severity Score (MSS) was calculated. All the patients were treated according to WHO guidelines.
RESULTS: Of them MS and Pf malaria constituted 118 (13.2%) and 770 (86.7%) patients respectively. Severe malaria was found in 17.8% (21 of 118) patients of MS and 57.1% (440 of 770) patients Pf malaria. Pf constituted 440 (95.5%) cases where as MS constituted 21 (4.5%) respectively. The number of severe malaria was significantly (p < 0.001) more in Pf than MS. Out of 21 cases of severe malaria in MS infection, 14 (66.6%) had single complication and 7 (33.3%) cases had multiple complication. However, in Pf mono infection there were 200 (45.5%) patients with single and 240 (54.5%) with multiple complication. There were 4 independent risk factors for a patient of developing complicated malaria. They were: presenting without fever, high parasite count, Pf mono infection, and fever to treatment interval. Multiple complications and high MSS are associated with increased death in Pf malaria. The outcome of patients of MS was good.
CONCLUSION: In conclusion mixed species infection is not uncommon in the locality where both species coexists. Mixed species infection can complicate with severe malaria. However, its incidence and severity is less than severe falciparum malaria. In mixed infection, P.vivax malaria has a protective effect against the severity of falciparum malaria.

Entities:  

Mesh:

Year:  2012        PMID: 23777020

Source DB:  PubMed          Journal:  J Assoc Physicians India        ISSN: 0004-5772


  11 in total

1.  The high risk of malarial recurrence in patients with Plasmodium-mixed infection after treatment with antimalarial drugs: a systematic review and meta-analysis.

Authors:  Aongart Mahittikorn; Frederick Ramirez Masangkay; Kwuntida Uthaisar Kotepui; Giovanni De Jesus Milanez; Manas Kotepui
Journal:  Parasit Vectors       Date:  2021-05-25       Impact factor: 3.876

2.  Detection of mixed infection level of Plasmodium falciparum and Plasmodium vivax by SYBR Green I-based real-time PCR in North Gondar, north-west Ethiopia.

Authors:  Addimas Tajebe; Gabriel Magoma; Mulugeta Aemero; Francis Kimani
Journal:  Malar J       Date:  2014-10-18       Impact factor: 2.979

3.  Clinical Profile and Prognostic Indicators in Adults Hospitalized with Severe Malaria Caused by Different Plasmodium Species.

Authors:  Bal Kishan Gupta; Anjli Gupta; Hardev Ram Nehra; Heera Ram Balotia; Shyam Lal Meena; Surendra Kumar
Journal:  Infect Dis (Auckl)       Date:  2015-12-06

4.  Prevalence of malaria in two highly endemic Community Health Centers in the Bastar district, Chhattisgarh showing mixed infections with Plasmodium species.

Authors:  Sri Krishna; Ajay Yadav; Sneha Bhandari; Anup K Vishwakarma; Praveen K Bharti; Prem L Mandavi; Pradeep Bahgel; Sanjay Basak; Ravendra K Sharma; Neeru Singh
Journal:  Sci Rep       Date:  2017-12-04       Impact factor: 4.379

5.  Comparison of the diagnostic performance of microscopic examination with nested polymerase chain reaction for optimum malaria diagnosis in Upper Myanmar.

Authors:  Jung-Mi Kang; Pyo-Yun Cho; Mya Moe; Jinyoung Lee; Hojong Jun; Hyeong-Woo Lee; Seong Kyu Ahn; Tae Im Kim; Jhang Ho Pak; Moe Kyaw Myint; Khin Lin; Tong-Soo Kim; Byoung-Kuk Na
Journal:  Malar J       Date:  2017-03-16       Impact factor: 2.979

6.  A Hospital-Based Retrospective Comparative Study of Complications, Outcomes, Clinical and Laboratory Parameters of Malaria with and without Neurological Involvement.

Authors:  Sohaib Ahmad; Nadia Shirazi; Nowneet K Bhat; Minakshi Dhar; Garima Mittal; Manish Mittal; Nidhi Kaeley; Manoj Kumar
Journal:  Mediterr J Hematol Infect Dis       Date:  2017-01-01       Impact factor: 2.576

7.  Malaria diagnosis by PCR revealed differential distribution of mono and mixed species infections by Plasmodium falciparum and P. vivax in India.

Authors:  Nisha Siwal; Upasana Shyamsunder Singh; Manoswini Dash; Sonalika Kar; Swati Rani; Charu Rawal; Rajkumar Singh; Anupkumar R Anvikar; Veena Pande; Aparup Das
Journal:  PLoS One       Date:  2018-03-22       Impact factor: 3.240

8.  Plasmodium spp. mixed infection leading to severe malaria: a systematic review and meta-analysis.

Authors:  Manas Kotepui; Kwuntida Uthaisar Kotepui; Giovanni De Jesus Milanez; Frederick Ramirez Masangkay
Journal:  Sci Rep       Date:  2020-07-06       Impact factor: 4.379

9.  Severity in Plasmodium vivax malaria claiming global vigilance and exploration--a tertiary care centre-based cohort study.

Authors:  Kavitha Saravu; Kumar Rishikesh; Asha Kamath; Ananthakrishna B Shastry
Journal:  Malar J       Date:  2014-08-08       Impact factor: 2.979

10.  Early treatment failure in concurrent dengue and mixed malaria species infection with suspected resistance to artemisinin combination therapy from a tertiary care center in Delhi: a case report.

Authors:  Rushika Saksena; Monika Matlani; Vineeta Singh; Amit Kumar; Anupam Anveshi; Dilip Kumar; Rajni Gaind
Journal:  Int Med Case Rep J       Date:  2017-08-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.